Skip to content

Released May 9, 2022, before the open

10-Q filed May 9, 2022, 39 days after period end · 0000950170-22-008244

Q1 2022 · 10-Q
Revenue—
Net Income-$7.16MN/M vs Q1 2021N/M vs Q4 2021
EPS Diluted-$0.07N/M vs Q1 2021no prior Q4 2021 on file
Operating Income-$7,182,000N/M
Operating Cash Flow-$7,942,000N/M
Free Cash Flowderived-$8,136,000N/M

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ1 2022Q1 2021Q1 2020Q1 2019
Net Income-$7.16M-$7.42M-$6.40M-$10.77M
EPS Diluted-$0.07-$0.14-$0.90—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR